IgG Anti-β2 Glycoprotein I Antibodies in Malaysian Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus: Prevalence and Clinical Correlations

2002 ◽  
Vol 21 (5) ◽  
pp. 382-385 ◽  
Author(s):  
S. G. Ong ◽  
H. M. Cheng ◽  
S. C. Soon ◽  
E. Goh ◽  
S. K. Chow ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Clinical Correlations

Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

2004 ◽  
Vol 92 (12) ◽  
pp. 1303-1311 ◽  
Author(s):  
Anthi Balitsari ◽  
John Routsias ◽  
Panayiotis G.Vlachoyiannopoulos ◽  
Clio Mavragani ◽  
Efi Bourazopoulou
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Amino Acid Position ◽  
Systemic Lupus ◽  
Multiple Antigenic Peptide ◽  
Glycoprotein I ◽  
Peptide Carrier ◽  
Intracellular Domains ◽  
Peptide Antibodies

SummaryAnti-β2glycoprotein I (anti-β2GPI) antibodies constitute the main autoantibody specificity in the sera of patients with antiphospholipid syndrome (APS). There is evidence that antiβ2GPI antibodies induce the precoagulant activity of the endothelium by cross-linking the β2 glycoprotein I (β2GPI) on the cell surface. Since β2GPI lacks intracellular domains, homology with other molecules such as CD40 that could initiate signaling, was extensively searched. A 86% homology between the amino acid position 239-245 of the CD40 and 7-13 of the β2glycoprotein was found. The CD40 peptide corresponding to amino acids 239-245 of the CD40 molecule was synthesized and coupled to a multiple antigenic peptide carrier. Antibodies to CD40 peptide were found in 61.5% APS patients (n=39), in 72.7% of systemic lupus erythematosus (SLE) positive for anti β2GPI antibodies (n=11) and 31.6% of SLE negative for antiβ2GPI antibodies (n=19), but not in rheumatoid arthritis patients (n=28) or controls (n=36). Antibodies to CD40 peptide were associated with arterial thrombosis and/or brain microinfarcts. Affinity purified anti-CD40 peptide antibodies as well as affinity purified anti-β2GPI antibodies recognized both, the β2GPI and the CD40 peptide. The specificity of this recognition was confirmed with homologous and heterologous inhibition experiments. Confocal microscopy experiments demonstrated this cross-recognition of CD40 and β2GPI molecules, by the purified anti-CD40 peptide antibodies, at the protein level. Thus, antibodies reacting with the β2GPI can react and potentially activate different cells which express CD40 molecules at their surface.

scholarly journals Systemic Lupus Erythematosus and Antiphospholipid Syndrome

2014 ◽  
Vol 2 (3) ◽  
pp. 544-549
Author(s):  
Aleksandra Plavsic ◽  
Rada Miskovic ◽  
Sanvila Raskovic ◽  
Mirjana Bogic ◽  
Branka Bonaci Nikolic
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Autoimmune Disorder ◽  
Systemic Lupus ◽  
Vascular Thrombosis ◽  
Glycoprotein I ◽  
Independent Entity ◽  
Acquired Thrombophilia

Antiphospholipid syndrome is an autoimmune disorder defined as association of vascular thrombosis and/or pregnancy complications with presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin and anti-β2 glycoprotein I). It is the most common cause of acquired thrombophilia, and can occur as an independent entity or in relation with other diseases, especially systemic lupus erythematosus. Presence of antiphospholipid syndrome in systemic lupus erythematosus is additional vaso occlusive factor in already present inflammation, bringing further risk for thrombotic events. Clinical and serological manifestations of antiphospholipid syndrome and systemic lupus erythematosus are very similar, so possible connection for these two autoimmune disorders is assumed.

Sign in / Sign up

Export Citation Format

Share Document